Department of Chemistry, The Ohio State University, 100 W. 18th St., Columbus, Ohio 43210, USA.
J Org Chem. 2011 Feb 18;76(4):1140-50. doi: 10.1021/jo102478x. Epub 2011 Jan 18.
Details of the evolution of strategies toward convergent assembly of the histone deacetylase inhibiting natural product largazole exploiting γ,δ-unsaturated-α,β-epoxy-aldehydes and a thiazole-thiazoline containing ω-amino-acid are described. The initial N-heterocyclic carbene mediated redox amidation exploying these two types of building blocks representing largazole's structural domains of distinct biosynthetic origin directly afforded the seco-acid of largazole. This was accomplished without any protecting groups resident upon either thioester bearing epoxy-aldehyde or the tetrapeptide. However, the ineffective production of largazole via the final macrolactonization led to an alternative intramolecular esterification/macrolactamization strategy employing the established two building blocks. This provided largazole along with its C2-epimer via an unexpected inversion of the α-stereocenter at the valine residue. The biological evaluation demonstrated that both largazole and 2-epi-largazole led to dose-dependent increases of acetylation of histone H3, indicating their potencies as class I histone deacetylase selective inhibitiors. Enhanced p21 expression was also induced by largazole and its C2 epimer. In addition, 2-epi-largazole displayed more potent activity than largazole in cell viability assays against PC-3 and LNCaP prostate cancer cell lines.
详细描述了利用γ,δ-不饱和-α,β-环氧醛和含噻唑-噻唑啉的ω-氨基酸对组蛋白去乙酰化酶抑制天然产物 largazole 进行收敛组装的策略演变。最初的 N-杂环卡宾介导的氧化酰胺化利用了这两种类型的构建块,它们分别代表 largazole 的不同生物合成起源的结构域,直接提供了 largazole 的 seco-酸。这是在硫酯基携带环氧醛或四肽上没有任何保护基团的情况下完成的。然而,由于最终的大环内酯化无效,导致采用已建立的两个构建块的替代分子内酯化/大环内酯化策略。该策略提供了 largazole 及其 C2-差向异构体,通过缬氨酸残基的α-立体中心的意外反转。生物评价表明 largazole 和 2-epi-largazole 均导致组蛋白 H3 的乙酰化程度呈剂量依赖性增加,表明它们作为 I 类组蛋白去乙酰化酶选择性抑制剂的效力。 largazole 及其 C2 差向异构体还诱导了 p21 表达的增强。此外,在针对前列腺癌 PC-3 和 LNCaP 细胞系的细胞活力测定中,2-epi-largazole 的活性比 largazole 更强。